A new oral drug, Rasonque, has received FDA approval for adults with metastatic pancreatic cancer who have no other treatment options. The approval is a rare step forward in a field with few effective therapies, but for now, access is limited to the United States.
Adults in the United States with metastatic pancreatic cancer now have a new oral treatment option: Rasonque. The FDA has approved this drug, which contains daraxonrasib, for patients whose disease has progressed after standard therapies. Pancreatic cancer is known for its poor prognosis and limited treatment choices, so any new option stands out.
Rasonque is not for everyone. The approval is limited to patients who have already tried at least one systemic therapy or cannot receive multi-drug regimens. It is not intended for early-stage cases or those who can benefit from established first-line treatments. The FDA based its decision on clinical trial data.
The RASolute 302 trial included 500 adults with metastatic pancreatic adenocarcinoma whose cancer had worsened after earlier treatment. Participants received either daraxonrasib or a standard chemotherapy chosen by their doctor. The main outcomes—overall survival and progression-free survival—were reviewed independently and formed the basis for the FDA's approval.
Daraxonrasib blocks the RAS GTPase family of proteins, which drive the growth of many pancreatic tumors. This pathway has been difficult to target with drugs, so Rasonque's approval is a technical achievement. Still, the drug is not risk-free, and its side effects are detailed in the FDA's official information.
For patients who meet the criteria, having an oral targeted therapy is a real change. Until now, most have faced harsh chemotherapies with limited results. Rasonque's once-daily tablet is also easier for those who cannot handle intensive intravenous treatments.
However, the FDA's decision does not affect patients outside the United States. In Spain and the rest of the European Union, Rasonque is not approved or available, and separate regulatory reviews and reimbursement decisions are still pending. Any suggestion that the drug will soon be available in Spanish hospitals is premature. As with recent policy changes affecting pensioners' work rights, regulatory timelines and priorities can differ widely between countries.
It is also important to note that FDA approval does not mean a cure. The agency's decision reflects that, for a specific group of patients, the benefits of Rasonque outweigh its risks. The drug has notable warnings and side effects, and it can only be prescribed by specialists—self-medication is not allowed.
For now, Rasonque offers a new option for some patients with few alternatives and shows that progress is possible even in difficult cancers. But access depends on geography and regulatory decisions. Until European authorities complete their reviews, patients and doctors in Spain and elsewhere will have to wait. For many, the FDA's approval is a step forward, but not an immediate solution.
